[1] Mak LY, Seto WK, Fung J, et al. Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. Hepatol Int, 2020, 14(1):35-46. [2] Belopolskaya M, Avrutin V, Kalinina O, et al. Chronic hepatitis B in pregnant women: current trends and approaches. World J Gastroenterol, 2021, 27(23):3279-3289. [3] Seto WK, Lo YR, Pawlotsky JM, et al. Chronic hepatitis B virus infection. Lancet, 2018, 392(10161):2313-2324. [4] Zhang J, Lin S, Jiang D, et al. Chronic hepatitis B and non-alcoholic fatty liver disease: conspirators or competitors? Liver Int, 2020, 40(3):496-508. [5] Wang K, Lu X, Zhou H, et al. Deep learning radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study. Gut, 2019, 68(4):729-741. [6] Yan Y, Xing X, Lu Q, et al. Assessment of biopsy proven liver fibrosis by two-dimensional shear wave elastography in patients with primary biliary cholangitis. Dig Liver Dis, 2020, 52(5):555-560. [7] Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol, 2020, 16(11):654-667. [8] Kurys-Denis E, Prystupa A, Luchowska-Kocot D, et al. PDGF-BB homodimer serum level - a good indicator of the severity of alcoholic liver cirrhosis. Ann Agric Environ Med, 2020, 27(1):80-85. [9] Sellers RA, Robertson DL, Tassabehji M. Ancestry of the AUTS2 family-a novel group of polycomb-complex proteins involved in human neurological disease. PLoS One, 2020, 15(12):e0232101. [10] 中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1):9-32. [11]中华肝脏病学会肝纤维化学组.肝纤维化诊断及疗效评估共识.中华肝脏病杂志,2002,10(5):327-328. [12] 孙振江,石伟珍,徐晶,等.血清miR-146基因多态性与乙型肝炎病毒感染患者肝硬化的易感性.中华医院感染学杂志,2021,31(17):2575-2578. [13] Qu C, Zheng D, Li S, et al. Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis. Hepatology, 2018, 68(3):1125-1139. [14] Agbim U, Asrani SK. Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers. Expert Rev Gastroenterol Hepatol, 2019, 13(4):361-374. [15] Coll M, Perea L, Boon R, et al. Generation of hepatic stellate cells from human pluripotent stem cells enables in vitro modeling of liver fibrosis. Cell Stem Cell, 2018, 23(1):101-113. [16] Schwabe RF, Tabas I, Pajvani UB. Mechanisms offibrosis development in nonalcoholic steatohepatitis. Gastroenterology, 2020, 158(7):1913-1928. [17] Kang H, Seo E, Park JM, et al. Effects of FGF21-secreting adipose-derived stem cells in thioacetamide-induced hepatic fibrosis. J Cell Mol Med, 2018, 22(10):5165-5169. [18] Chen Z, Jain A, Liu H, et al. Targeted drug delivery to hepatic stellate cells for the treatment of liver fibrosis. J Pharmacol Exp Ther, 2019, 370(3):695-702. [19] Chen Z, Yao L, Liu Y, et al. Astragaloside IV regulatesNF-κB-mediated cellular senescence and apoptosis of hepatic stellate cells to suppress PDGF-BB-induced activation. Exp Ther Med, 2019, 18(5):3741-3750. [20] Shah R, Reyes-Gordillo K, Rojkind M. Thymosin β4 inhibits PDGF-BB induced activation, proliferation, and migration of human hepatic stellate cells via its actin-binding domain. Expert Opin Biol Ther, 2018, 18(supl 1):177-184. |